Quetiapine is indicated for the following conditions-

• Schizophrenia 
• Bipolar Disorder 

Schizophrenia

Bipolar Disorder

Schizophrenia-Adults

• Initial Dose: 25 mg twice daily 
• Recommended Dose: 150-750 mg/day
• Maximum  Dose: 750 mg/day 

Schizophrenia (Adolescents)

• Initial Dose:25 mg twice daily  
• Recommended Dose: 400-800 mg/day
• Maximum  Dose: 800 mg/day

Bipolar Mania-Adults Monotherapy or as an adjunct to lithium or divalproex

• Initial Dose: 50 mg twice daily
• Recommended Dose: 400– 800 mg/day 
• Maximum Dose: 800 mg/day 

Bipolar Mania Children and Adolescents (10 to 17 years), Monotherapy

• Initial Dose: 25 mg twice daily  
• Recommended Dose: 400-600 mg/day
• Maximum  Dose: 600 mg/day 

Bipolar Depression (Adults)

• Initial Dose: 50 mg once daily at bedtime
• Recommended Dose: 300 mg/day
• Maximum  Dose: 300 mg/day

Most commonly reported side effects associated with the use of Quetiapine include-

• Dizziness
• somnolence
• headache
• extrapyramidal symptoms
• Dry mouth
• hypertriglyceridemia
• hypercholesterolemia
• Weight gain
• Leucopenia
• decreased neutrophil count
• eosinophilia

Dizziness	Somnolence	Headache	Dry Mouth
Weight Gain	Leukopenia	Eosinophilia	Primary Hypercholesterolemia

• Cerebrovascular Adverse Reactions: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs
• Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring
• Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain 
• Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes 
• Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics. Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of, and periodically, during treatment
• Weight Gain: Gain in body weight has been observed; clinical monitoring of weight is recommended
• Tardive Dyskinesia: Discontinue if clinically appropriate 
• Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease
• Increased Blood Pressure in Children and Adolescents: Monitor blood pressure at the beginning of, and periodically during treatment in children and adolescents
• Leukopenia, Neutropenia and Agranulocytosis: Monitor complete blood count frequently during the first few months of treatment in patients with a pre-existing low white cell count or a history of leukopenia/neutropenia and discontinue Quetiapine at the first sign of a decline in WBC in absence of other causative factors
• Cataracts: Lens changes have been observed in patients during long-term quetiapine treatment. Lens examination is recommended when starting treatment and at 6-month intervals during chronic treatment